ReviewNature reviews. Clinical oncology2021
Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.
Review in Nature reviews. Clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 205 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
205 citing papers in PubMed, 6 syntheses or guidelines pooled it, 377 citations in OpenAlex.
- The efficacy and safety of neoadjuvant immunochemotherapy in resectable stage I-III non-small cell lung cancer: a systematic review and network meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- AI models for the identification of prognostic and predictive biomarkers in lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Bibliometric insight into neoadjuvant immunotherapy in non-small cell lung cancer: trends, collaborations, and future avenues.Frontiers in immunology · 2025Pooled it
- Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.JAMA oncology · 2024Pooled it
- A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review).International journal of oncology · 2024Pooled it
- Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.European journal of clinical pharmacology · 2024Pooled it
- Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.Nature communications · 2025Trial
- Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief Report.International journal of radiation oncology, biology, physics · 2025Trial
- Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer.Journal for immunotherapy of cancer · 2024Trial
- Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.Nature medicine · 2023Trial
- Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.Nature communications · 2021Trial
- The Efficacy of Adjuvant EGFR-TKI Therapy for Stage IA Lung Adenocarcinoma with EGFR Mutations: A Retrospective Cohort Study.Annals of surgical oncology · 2026Article
- Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation.Signal transduction and targeted therapy · 2026Review
- Cisplatin-Resistant Lung Adenocarcinoma Cells Exhibit Increased Proangiogenic Capacity in a Microphysiological Model of Tumor Neovascularization.Cancer medicine · 2026Article
- Effect of Interval Between Neoadjuvant Immunochemotherapy and Radical Resection of Non-Small Cell Lung Cancer: A Multicenter, Retrospective Cohort Study.International journal of cancer · 2026Article
- Recent advances in engineered nanozymes for precision lung cancer therapy.Materials today. Bio · 2026Review
- Perioperative Systemic Therapies in Resectable Non-Small Cell Lung Cancer: Opportunities and Challenges.Journal of clinical medicine · 2026Review
- Article
- Induction alectinib or crizotinib for stage III NSCLC harboring ALK fusion: A study with 4-year follow-up.Chinese medical journal · 2026Article
- Single-cell transcriptomic analysis reveals that the circRNA circGCLM promotes tumorigenesis and confers cisplatin resistance in NSCLC through the miR-505-3p/ERBB4 axis.Translational oncology · 2026Article
145 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary discussions of surgical resectability and medical operability determine the modality of definitive local treatment (surgery or radiotherapy) and the associated systemic therapies to further improve the likelihood of cure. Trial evidence supports cisplatin-based adjuvant therapy either after surgical resection or concurrently with radiotherapy. Consensus guidelines support neoadjuvant chemotherapy in lieu of adjuvant chemotherapy and carboplatin-based regimens for patients who are ineligible for cisplatin. The incorporation of newer agents, now standard for patients with stage IV lung cancer, into the curative therapy paradigm has lagged owing to inefficient trial designs, the lengthy follow-up needed to assess survival end points and a developmental focus on the advanced-stage disease setting. Surrogate end points, such as pathological response, are being studied and might shorten trial durations. In 2018, the anti-PD-L1 antibody durvalumab was approved for patients with stage III lung cancer after concurrent chemoradiotherapy. Since then, the study of targeted therapies and immunotherapies in patients with early-stage lung cancer has rapidly expanded. In this Review, we present the current considerations in the treatment of patients with early-stage lung cancer and explore the current and future state of clinical research to develop systemic therapies for non-metastatic lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.